Insider buying last 90 days
No open-market insider purchases were filed for ZTS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ZTS insider filing, plotted on the chart in Gekko.Open ZTS in Gekko
Gekko Brief
AI summaryNov 4 closeZoetis shares have climbed through the week, rising 4.34% to $83.18 in one session and extending a streak of consecutive gains, with coverage framing Q3 and Q4 expectations as notably low and potentially beatable given the company's diversified growth levers. Reporting ahead of the open on 5 November, management and analyst previews point to international growth, livestock strength and demand for companion animal products as offsetting challenges in the U.S. market, while prior commentary from the August call flagged competitive intensity, gross-to-net promotions, and continued R&D investment behind products such as Apoquel, Trio and Cytopoint.
Zoetis closed at $89.20, up 7.5%, with the stock sitting between its 50-day average of $75.51 and its 200-day average of $92.94. The GekkoIndex reads 40.3, placing the stock in the Distribution zone and down 13.9 over five periods. Against a Gekko Fair Value of $113.67, the current price leaves a gap of -21.5%.
Earnings arrive 5 November, zero days away, placing the report inside the next 20-trading-day window; the last print beat estimates ($1.87 vs $1.84) but still drew a -2.3% reaction, and average absolute moves around earnings have run 8%. Congress activity over the past 90 days shows 2 buys and 0 sales. Seasonally, the next 20 trading days have averaged +6.1% over 5 years, rising in 4 of them. Analyst consensus stands at 4 buy, 6 hold, 0 sell ratings with a consensus target of $88.38.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Zoetis price vs fair value
Close $89.20200-day averageGekko Fair Value $113.67
Zoetis quick facts
- Market cap
- $36.85B
- P/E ratio
- 13.1
- Forward P/E
- 13.4
- EPS, TTM
- $6.34
- Revenue, TTM
- $9.53B
- Profit margin
- 27.7%
- Dividend yield
- 2.58%
- Beta
- 0.68
- Volume
- 9.17M avg 4.02M
- 1-year return
- −38.2%
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±4.9%
- 50-day average
- $75.51
- 200-day average
- $92.94
- Next earnings
- Nov 5 before open
- Shares outstanding
- 413.2M
Zoetis swing-trade checklist
Zoetis scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $89.20 sits between the 50-day ($75.51) and 200-day ($92.94) averages, or the averages disagree.
See the chart - GekkoIndexheadwind
40.3, Distribution
Reading 40.3 is in the Distribution zone.
See the GekkoIndex - Fair valuesupportive
21.5% below
Price is 21.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 2 buys / 0 sales.
See smart money - Earnings riskheadwind
Reports today
Reports on Nov 5, 2026, today — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+6.1% on average
From this point in the calendar, the next 20 trading days averaged +6.1% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Zoetis stock chart and price history
Zoetis closed at $89.20 on Nov 4, 2026, −38.2% over the past year, inside a 52-week range of $68.77 to $132.49.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +25.1%
- 3 months
- +15.4%
- 6 months
- −19.8%
- 1 year
- −38.2%
The full ZTS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ZTS in Gekko
Follow Zoetis through every session
Put ZTS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ZTS in GekkoFree for 7 days. No credit card required.
About Zoetis
Zoetis develops and produces health products for animals, covering both farm livestock and household pets. Its work spans medicines, vaccines, and diagnostic equipment used to prevent and treat disease across species such as cattle, swine, poultry, fish, sheep, dogs, cats, and horses. The company is known for combining treatment products with tools that detect and monitor illness in animals.
Its offerings include vaccines that guard against respiratory, digestive, and reproductive conditions, along with anti-infectives and parasite treatments for pests like fleas, ticks, and worms. Other products cover pain relief, sedation, nausea control, reproductive care, cancer treatment, and skin conditions such as allergies and dermatitis, plus feed additives for livestock. On the diagnostic side, Zoetis makes portable and point-of-care testing devices, laboratory reagents, immunoassay kits, reference lab services, and glucose monitors, alongside nutritional products, genetic testing, and precision health tools. Customers include veterinarians, livestock producers, and retail outlets, reached through its own sales teams as well as outside distributors.
Zoetis was founded in 1952 and is headquartered in Parsippany, New Jersey. Its shares are listed on the NYSE under the ticker ZTS.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- zoetis.com
Zoetis GekkoIndex: the smart money zone
Zoetis’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 40.3, in the Distribution zone, down 13.9 points over five sessions.
40.3Distribution
Down 13.9 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 65 | +1.1% | +1.4% | ||
| Accumulation | 302 | −0.8% | −1.8% | ||
| Neutral | 323 | −0.6% | −3.4% | ||
| Distribution (current zone) | 6 | Too few readings yet | |||
| Selling | 1 | Too few readings yet | |||
Average ZTS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the ZTS price, zone by zone.Track ZTS in Gekko
Is Zoetis stock overvalued? Gekko Fair Value
Zoetis trades 21.5% below Gekko Fair Value of $113.67, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Zoetis shares are worth, recalculated every trading day.
$113.67
Gekko Fair Value, Nov 4, 2026
21.5% Undervalued
At the end of Aug 2026 the price was 39.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ZTS in Gekko
Zoetis insider and Congress trading
No open-market insider purchases were filed for Zoetis, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Oct 12 traded Sep 18 |
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Zoetis has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $584.0M
- As a share of market cap
- 1.58%
- Trailing four quarters
- $3.64B
From company filings.
Hedge funds and billionaires quarter ended Sep 30
2of the funds Gekko tracks hold ZTS.
1added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Zoetis earnings: next date and track record
Zoetis reports on Nov 5, 2026, before the open (today), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, today
- EPS estimate
- $1.51
- Revenue estimate
- $2.30B
7 of 8reports beat the EPS estimate
±8%average move across the report
0 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Zoetis Q2 2026 earnings call covered macro headwinds in Companion Animal market, competitive intensity and targeted pricing actions, financial results, cost control measures, and livestock strength. Management emphasized gross-to-net promotions to protect volume and share, defended product differentiation (Apoquel, Trio, Cytopoint), and highlighted continued R&D investment. CFO Wetteny Joseph detailed results: Q2 revenue $2.5B (flat reported, -1% organic), adjusted net income $781M (-2% organic), Companion Animal revenue $1.7B (-6%), Dermatology $395M (-16%), OA pain mAbs $147M (-3%). Management revised full-year guidance reflecting persistent competitive/promotional activity and FX headwinds (~$60-65M top-line, ~$30M bottom-line). Livestock performed strongly (global +11%, U.S. +23%), with normalized growth expected mid- to high-single digits. Management signaled ongoing cost actions (SG&A -4% YoY) and gross margin protection but expects pricing/headwinds to pressure near-term results; they remain confident long-term.
- Guidance
- Revised 2026 guidance: revenue guide range implies price realization of roughly 0% to -1% on the mid-to-high end and potentially -2% toward the low end; FX headwind of ~$60-65M top-line (~$30M bottom-line). No 2027 guidance provided.
- Risks flagged
- Headwinds include: declining veterinary clinic visits and pet owner affordability pressures; increased competitive intensity with discounting and promotional tactics; potential continued market contraction in Dermatology and parasiticides; FX translation headwinds (~$60-65M top-line).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $1.87 est $1.84 | $2.47B est $2.50B | −2.3% |
| May 7, 2026 | $0.00 est $1.57 | $2.26B est $2.30B | −25.5% |
| Feb 12, 2026 | $1.48 est $1.40 | $2.39B est $2.36B | −1.6% |
| Nov 4, 2025 | $1.70 est $1.64 | $2.40B est $2.41B | −16.5% |
| Aug 5, 2025 | $1.76 est $1.62 | $2.46B est $2.41B | −3.5% |
| May 6, 2025 | $1.48 est $1.41 | $2.22B est $2.19B | −1.3% |
| Feb 13, 2025 | $1.40 est $1.36 | $2.32B est $2.30B | −9.4% |
| Nov 4, 2024 | $1.58 est $1.46 | $2.39B est $2.29B | −3.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Zoetis stock forecast and analyst price targets
Analysts’ average 12-month price target for Zoetis is $88.38, −0.9% from the last close, from 10 firms rating the stock in the last 90 days.
$88.38consensus 12-month target, −0.9% from the last close
Now $89.20Avg $88.38
Low $80High $115
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 29 | Morgan Stanley | $85 | −4.7% |
| Oct 29 | Morgan Stanley | $82 | −8.1% |
| Oct 27 | UBS | $85 | −4.7% |
| Oct 16 | J.P. Morgan | $115 | +28.9% |
| Oct 1 | Leerink Partners | — | — |
+6.1%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Zoetis seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Zoetis averaged +6.1% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.3% | 3 of 5 |
| Next 10 trading days | +3.2% | 4 of 5 |
| Next 15 trading days | +5.3% | 5 of 5 |
| Next 20 trading days | +6.1% | 4 of 5 |
| Next 30 trading days | +6.3% | 3 of 5 |
For scale, ZTS’s typical 20-trading-day move in either direction is about 4.9%.
Zoetis market cap and key statistics
Zoetis’s market cap is $36.85B, with a P/E ratio of 13.1 and revenue of $9.53B over the last twelve months.
Valuation
- Market cap
- $36.85B
- P/E ratio
- 13.1
- Forward P/E
- 13.4
- EPS, TTM
- $6.34
- Gekko Fair Value
- $113.67
Trading
- Volume
- 9.17M
- Avg volume, 20 days
- 4.02M
- 52-week high
- $132.49
- 52-week low
- $68.77
- Shares outstanding
- 413.2M
Financials
- Revenue, TTM
- $9.53B
- Profit margin
- 27.7%
- Return on equity
- 64.9%
- Quarterly earnings growth, YoY
- +1.2%
Risk and income
- Beta
- 0.68
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±4.9%
- Dividend yield
- 2.58%
Zoetis stock news this week
5 headlines about Zoetis from the past week, newest first, each linking to the publisher.
- Zoetis: Near-Term Expectations More Achievable, Long Growth Runway UndervaluedSeeking Alpha, Nov 4
- Zoetis Gears Up to Report Q3 Earnings: Here's What to ExpectZacks Investment Research, Nov 3
- Insights Into Zoetis (ZTS) Q3: Wall Street Projections for Key MetricsZacks Investment Research, Nov 3
- Zoetis Inc. stock outperforms competitors on strong trading dayMarketWatch, Nov 2
- Zoetis (ZTS) Ascends While Market Falls: Some Facts to NoteZacks Investment Research, Oct 29
Zoetis peers
Zoetis’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| JNJJohnson & Johnson | Neutral | 1.7% below |
| ABBVAbbVie | Neutral | 26.5% above |
| MRKMerck | Neutral | 8.6% below |
| AZNAstraZeneca | Distribution | 34.1% below |
| PFEPfizer | Neutral | 4.1% below |
A peer links to its own page where one exists.
Zoetis stock FAQ
What is Zoetis’s market cap?
Zoetis’s market cap is $36.85B at the Nov 4, 2026 close of $89.20, with 413.2M shares outstanding. The shares trade on a P/E ratio of 13.1.
What is the Zoetis stock forecast?
The consensus analyst 12-month price target for Zoetis is $88.38, −0.9% from the last close. Of the 10 firms that rated the stock in the last 90 days, 4 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Zoetis stock overvalued or undervalued?
On Gekko’s estimate Zoetis is undervalued: the Nov 4, 2026 close of $89.20 is 21.5% below Gekko Fair Value of $113.67. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Zoetis report earnings next?
Zoetis is expected to report on Nov 5, 2026, before the market opens (today). Analysts expect earnings of $1.51 per share on revenue of $2.30B. Zoetis beat the earnings estimate in 7 of its last 8 reports, moving 8% on average across the report.
What is Zoetis’s 52-week high and low?
Zoetis’s 52-week high is $132.49 and its 52-week low is $68.77; it closed at $89.20 on Nov 4, 2026, −38.2% over the past year. Over the last five years the shares peaked at $249.27 on Dec 30, 2021.
Is Zoetis stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (fair value, smart money and seasonality), 1 as mixed (trend) and 2 as headwinds (gekkoindex and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Zoetis the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.